Exane Derivatives’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Exane Derivatives’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$517K	Buy	6,963 +6,000	+623%	+$450K	0.3%	83
2022 Q1	$86.5K	Hold	963	–	–	0.02%	489
2021 Q4	$108K	Hold	963	–	–	0.03%	433
2021 Q3	$121K	Buy	963 +62	+7%	+$7.98K	0.03%	500
2021 Q2	$117K	Hold	901	–	–	0.03%	522
2021 Q1	$122K	Hold	901	–	–	0.03%	390
2020 Q4	$127K	Sell	901 -199	-18%	-$25.5K	0.04%	361
2020 Q3	$123K	Buy	+1,100	New	+$123K	0.04%	274

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Exane Derivatives's XBI Position: Q2 2022 in Review

Exane Derivatives increased its State Street SPDR S&P Biotech ETF (XBI) stake by 623% in Q2 2022, buying an estimated $450K and bringing the position to 6,963 shares worth $517K. The position accounts for 0.3% of the portfolio, ranked #83.

Exane Derivatives first reported a position in XBI in Q3 2020 and has held it in 8 quarters since. 706 funds tracked by Wall St. Rank hold XBI as of Q2 2022.

Exane Derivatives held 6,963 shares of State Street SPDR S&P Biotech ETF worth $517K as of Q2 2022.
Exane Derivatives bought 6,000 State Street SPDR S&P Biotech ETF shares in Q2 2022, an estimated $450K.
State Street SPDR S&P Biotech ETF made up 0.3% of Exane Derivatives's portfolio in Q2 2022, its #83 holding.
Exane Derivatives first reported a position in State Street SPDR S&P Biotech ETF in Q3 2020 and has held it in 8 quarters since.
706 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.